Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Heterocyclic Compounds, 3-Ring | 12 | 2019 | 275 | 4.53 | Why? |
| Anti-HIV Agents | 18 | 2019 | 2209 | 3.46 | Why? |
| Rilpivirine | 3 | 2018 | 65 | 2.08 | Why? |
| HIV Infections | 27 | 2019 | 11620 | 1.92 | Why? |
| Darunavir | 4 | 2018 | 477 | 1.71 | Why? |
| Oxazines | 11 | 2019 | 279 | 1.25 | Why? |
| HIV Protease Inhibitors | 3 | 2018 | 434 | 1.16 | Why? |
| Piperazines | 11 | 2019 | 445 | 1.13 | Why? |
| Cobicistat | 5 | 2019 | 172 | 1.09 | Why? |
| HIV Integrase Inhibitors | 4 | 2018 | 173 | 0.99 | Why? |
| Antiretroviral Therapy, Highly Active | 4 | 2019 | 952 | 0.97 | Why? |
| Pyridones | 11 | 2019 | 738 | 0.94 | Why? |
| Oxidants | 1 | 2020 | 72 | 0.86 | Why? |
| HIV-1 | 9 | 2019 | 3365 | 0.79 | Why? |
| Cryoglobulins | 1 | 2018 | 51 | 0.74 | Why? |
| CD4-CD8 Ratio | 1 | 2018 | 235 | 0.68 | Why? |
| Lamivudine | 1 | 2019 | 210 | 0.68 | Why? |
| Nipah Virus | 1 | 2018 | 121 | 0.67 | Why? |
| Cyclohexanes | 1 | 2017 | 43 | 0.66 | Why? |
| Henipavirus Infections | 1 | 2018 | 122 | 0.65 | Why? |
| Cryoglobulinemia | 1 | 2018 | 144 | 0.65 | Why? |
| HIV Fusion Inhibitors | 1 | 2017 | 80 | 0.63 | Why? |
| Drugs, Generic | 1 | 2017 | 136 | 0.59 | Why? |
| Hydrogen Peroxide | 1 | 2020 | 680 | 0.58 | Why? |
| Tenofovir | 4 | 2019 | 449 | 0.57 | Why? |
| Hepatitis C, Chronic | 3 | 2019 | 973 | 0.56 | Why? |
| Drug Therapy, Combination | 12 | 2019 | 7268 | 0.54 | Why? |
| Triazoles | 1 | 2017 | 440 | 0.48 | Why? |
| HIV | 2 | 2019 | 1116 | 0.48 | Why? |
| Drug Resistance, Viral | 4 | 2018 | 1083 | 0.41 | Why? |
| Communicable Diseases, Imported | 1 | 2018 | 843 | 0.40 | Why? |
| Drug Interactions | 6 | 2019 | 1653 | 0.40 | Why? |
| Ritonavir | 4 | 2020 | 4212 | 0.39 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2018 | 1138 | 0.38 | Why? |
| Carrier State | 1 | 2020 | 2100 | 0.36 | Why? |
| Malaria | 1 | 2018 | 1097 | 0.36 | Why? |
| Adenine | 3 | 2019 | 463 | 0.33 | Why? |
| Anus Neoplasms | 1 | 2008 | 123 | 0.31 | Why? |
| Drug Substitution | 2 | 2018 | 385 | 0.27 | Why? |
| Communicable Diseases, Emerging | 1 | 2018 | 2523 | 0.26 | Why? |
| Protease Inhibitors | 2 | 2017 | 3630 | 0.26 | Why? |
| Papillomaviridae | 1 | 2008 | 404 | 0.26 | Why? |
| Quinolones | 3 | 2019 | 167 | 0.25 | Why? |
| Sustained Virologic Response | 3 | 2019 | 378 | 0.24 | Why? |
| Tablets | 2 | 2019 | 219 | 0.23 | Why? |
| Emtricitabine | 2 | 2019 | 202 | 0.22 | Why? |
| Hepatitis C | 3 | 2018 | 1514 | 0.22 | Why? |
| Developing Countries | 1 | 2017 | 4283 | 0.22 | Why? |
| Hepacivirus | 4 | 2018 | 1509 | 0.21 | Why? |
| Metformin | 2 | 2018 | 640 | 0.21 | Why? |
| Drug Combinations | 4 | 2020 | 3852 | 0.21 | Why? |
| Preliminary Data | 1 | 2021 | 457 | 0.19 | Why? |
| Antitoxins | 1 | 2018 | 10 | 0.19 | Why? |
| Alkynes | 1 | 2018 | 98 | 0.19 | Why? |
| Antiviral Agents | 9 | 2020 | 41703 | 0.19 | Why? |
| Italy | 15 | 2020 | 38444 | 0.19 | Why? |
| Hyperlactatemia | 1 | 2018 | 13 | 0.19 | Why? |
| Complement C4 | 1 | 2018 | 86 | 0.18 | Why? |
| Benzoxazines | 1 | 2018 | 103 | 0.18 | Why? |
| CD4 Lymphocyte Count | 3 | 2019 | 1517 | 0.18 | Why? |
| Humans | 54 | 2021 | 930598 | 0.18 | Why? |
| Lost to Follow-Up | 1 | 2017 | 79 | 0.18 | Why? |
| Therapeutic Equivalency | 1 | 2017 | 64 | 0.17 | Why? |
| Medication Adherence | 2 | 2017 | 1270 | 0.17 | Why? |
| Genotype | 5 | 2018 | 4697 | 0.17 | Why? |
| Skin Diseases, Bacterial | 1 | 2017 | 105 | 0.16 | Why? |
| Treatment Outcome | 11 | 2020 | 51732 | 0.16 | Why? |
| Immune System Diseases | 1 | 2021 | 410 | 0.16 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2018 | 8843 | 0.16 | Why? |
| Bone Density | 1 | 2019 | 335 | 0.16 | Why? |
| Equilibrative Nucleoside Transporter 1 | 1 | 2015 | 5 | 0.16 | Why? |
| Hair | 1 | 2018 | 175 | 0.16 | Why? |
| Cyclopropanes | 1 | 2018 | 332 | 0.16 | Why? |
| Salvage Therapy | 1 | 2018 | 417 | 0.15 | Why? |
| Complement C3 | 1 | 2018 | 271 | 0.15 | Why? |
| Pyrophosphatases | 1 | 2015 | 39 | 0.15 | Why? |
| Primates | 1 | 2018 | 584 | 0.15 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2017 | 256 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Viral Nonstructural Proteins | 3 | 2018 | 4810 | 0.15 | Why? |
| Middle Aged | 25 | 2020 | 270681 | 0.14 | Why? |
| Lopinavir | 2 | 2020 | 4308 | 0.14 | Why? |
| Alanine | 4 | 2020 | 5687 | 0.14 | Why? |
| Cost Savings | 1 | 2017 | 296 | 0.14 | Why? |
| Inflammatory Bowel Diseases | 3 | 2021 | 3209 | 0.14 | Why? |
| Cholesterol, HDL | 1 | 2018 | 439 | 0.14 | Why? |
| Ribavirin | 3 | 2017 | 1182 | 0.14 | Why? |
| Carbapenems | 1 | 2017 | 343 | 0.14 | Why? |
| Health Services Accessibility | 2 | 2019 | 10697 | 0.13 | Why? |
| Cholesterol, LDL | 1 | 2018 | 499 | 0.13 | Why? |
| Virus Shedding | 2 | 2020 | 5834 | 0.13 | Why? |
| Male | 27 | 2020 | 367725 | 0.13 | Why? |
| Drug Costs | 1 | 2017 | 313 | 0.13 | Why? |
| Anti-Bacterial Agents | 4 | 2020 | 10083 | 0.12 | Why? |
| Female | 25 | 2020 | 380317 | 0.12 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.12 | Why? |
| Health Plan Implementation | 1 | 2016 | 571 | 0.11 | Why? |
| Klebsiella pneumoniae | 1 | 2017 | 658 | 0.11 | Why? |
| United States Food and Drug Administration | 1 | 2018 | 1276 | 0.11 | Why? |
| Clostridium Infections | 1 | 2018 | 595 | 0.11 | Why? |
| Alanine Transaminase | 1 | 2017 | 1329 | 0.11 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2019 | 10649 | 0.10 | Why? |
| Viral Load | 4 | 2019 | 15850 | 0.10 | Why? |
| Disease Outbreaks | 1 | 2018 | 27595 | 0.10 | Why? |
| Adult | 15 | 2020 | 244371 | 0.10 | Why? |
| Emigrants and Immigrants | 1 | 2018 | 888 | 0.10 | Why? |
| Multiple Myeloma | 1 | 2018 | 1064 | 0.09 | Why? |
| Antirheumatic Agents | 2 | 2020 | 3023 | 0.09 | Why? |
| Seroconversion | 1 | 2018 | 2515 | 0.09 | Why? |
| Genomics | 1 | 2020 | 3118 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2017 | 1414 | 0.09 | Why? |
| Rheumatic Diseases | 2 | 2021 | 2675 | 0.08 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.08 | Why? |
| RNA, Messenger | 1 | 2021 | 5131 | 0.08 | Why? |
| Cost-Benefit Analysis | 1 | 2017 | 2259 | 0.08 | Why? |
| Patient Compliance | 1 | 2016 | 1468 | 0.08 | Why? |
| Autoimmune Diseases | 1 | 2020 | 1996 | 0.08 | Why? |
| Critical Pathways | 1 | 2016 | 1587 | 0.08 | Why? |
| Antimalarials | 1 | 2018 | 2505 | 0.08 | Why? |
| World Health Organization | 1 | 2018 | 4213 | 0.07 | Why? |
| Skin Diseases | 2 | 2021 | 2509 | 0.07 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.07 | Why? |
| Aged | 13 | 2020 | 215776 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2017 | 2165 | 0.07 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.07 | Why? |
| Radiography, Thoracic | 1 | 2020 | 5486 | 0.06 | Why? |
| Guidelines as Topic | 1 | 2016 | 2844 | 0.06 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Retrospective Studies | 6 | 2020 | 105322 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| Sofosbuvir | 2 | 2017 | 518 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.06 | Why? |
| Immunosuppressive Agents | 1 | 2020 | 6331 | 0.06 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.05 | Why? |
| Nasopharynx | 1 | 2020 | 10224 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Transaminases | 1 | 2020 | 152 | 0.05 | Why? |
| CCR5 Receptor Antagonists | 1 | 2019 | 66 | 0.05 | Why? |
| Travel | 1 | 2018 | 7220 | 0.05 | Why? |
| Prescriptions | 1 | 2020 | 258 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.05 | Why? |
| Respiratory Insufficiency | 1 | 2020 | 7301 | 0.05 | Why? |
| Mass Screening | 1 | 2019 | 8005 | 0.05 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.05 | Why? |
| Animals | 2 | 2018 | 78931 | 0.04 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.04 | Why? |
| Glomerulonephritis | 1 | 2021 | 226 | 0.04 | Why? |
| Uveitis | 1 | 2021 | 233 | 0.04 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.04 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.04 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.04 | Why? |
| Aminoglycosides | 1 | 2017 | 94 | 0.04 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.04 | Why? |
| Simeprevir | 1 | 2017 | 62 | 0.04 | Why? |
| Raltegravir Potassium | 1 | 2018 | 132 | 0.04 | Why? |
| Expert Testimony | 1 | 2021 | 658 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2017 | 264 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Longevity | 1 | 2018 | 159 | 0.04 | Why? |
| Fluoroquinolones | 1 | 2017 | 235 | 0.04 | Why? |
| Cell Culture Techniques | 1 | 2020 | 704 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2017 | 6166 | 0.04 | Why? |
| RNA, Viral | 3 | 2018 | 32276 | 0.04 | Why? |
| Placebos | 1 | 2018 | 629 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Colistin | 1 | 2017 | 217 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.04 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.03 | Why? |
| Interferons | 2 | 2017 | 2885 | 0.03 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.03 | Why? |
| Genome, Bacterial | 1 | 2017 | 446 | 0.03 | Why? |
| Delphi Technique | 1 | 2018 | 1257 | 0.03 | Why? |
| Oligopeptides | 1 | 2017 | 576 | 0.03 | Why? |
| Intensive Care Units | 1 | 2020 | 29594 | 0.03 | Why? |
| Depression | 1 | 2018 | 14116 | 0.03 | Why? |
| Proline | 1 | 2015 | 345 | 0.03 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.03 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2017 | 3607 | 0.03 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.03 | Why? |
| Psychotropic Drugs | 1 | 2018 | 396 | 0.03 | Why? |
| Regression Analysis | 1 | 2020 | 2484 | 0.03 | Why? |
| Antidepressive Agents | 1 | 2018 | 509 | 0.03 | Why? |
| Klebsiella Infections | 1 | 2017 | 466 | 0.03 | Why? |
| United States | 1 | 2018 | 46150 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2018 | 25288 | 0.03 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2020 | 11367 | 0.03 | Why? |
| beta-Lactamases | 1 | 2017 | 759 | 0.03 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.03 | Why? |
| Treatment Failure | 1 | 2017 | 2106 | 0.03 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 37182 | 0.03 | Why? |
| Administration, Oral | 1 | 2017 | 2340 | 0.02 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.02 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.02 | Why? |
| Hemoglobins | 1 | 2015 | 958 | 0.02 | Why? |
| Child | 1 | 2018 | 70012 | 0.02 | Why? |
| Young Adult | 2 | 2018 | 93724 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Glycated Hemoglobin A | 1 | 2017 | 1316 | 0.02 | Why? |
| Kinetics | 1 | 2017 | 3238 | 0.02 | Why? |
| Taste Disorders | 1 | 2020 | 1720 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2017 | 1318 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.02 | Why? |
| Self Report | 1 | 2020 | 3802 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2018 | 4260 | 0.02 | Why? |
| Anemia | 1 | 2015 | 789 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.02 | Why? |
| Lung Diseases | 1 | 2021 | 2361 | 0.02 | Why? |
| Incidence | 2 | 2019 | 25622 | 0.02 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.02 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2017 | 3239 | 0.02 | Why? |
| Gastrointestinal Diseases | 1 | 2020 | 2580 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2018 | 6543 | 0.02 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.02 | Why? |
| Computational Biology | 1 | 2020 | 4514 | 0.02 | Why? |
| Patient Discharge | 1 | 2020 | 5696 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Comorbidity | 2 | 2019 | 34796 | 0.02 | Why? |
| China | 2 | 2020 | 50654 | 0.02 | Why? |
| Fever | 1 | 2020 | 7795 | 0.02 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.01 | Why? |
| Acute Kidney Injury | 1 | 2020 | 5762 | 0.01 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Age Factors | 1 | 2020 | 21039 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.01 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Mutation | 1 | 2017 | 12376 | 0.01 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.01 | Why? |